Skip to main content
. 2021 Apr 13;12:650708. doi: 10.3389/fimmu.2021.650708

Figure 5.

Figure 5

Baricitinib treatment has an immunoregulatory effect on the spleen of experimental autoimmune encephalomyelitis (EAE) mice. Splenic mononuclear cells (MNCs) were isolated for flow cytometry to analyze the percentage of CD4+IFN-γ+ Th1 (A), CD4+IL-4+ Th2 (B), CD4+IL-17+ Th17 (C), and CD4+CD25+Foxp3+ Treg cells (D) at the peak phase of EAE. The percentages of Th1 and Th17 cells in the splenic MNCs were decreased in baricitinib-treated mice compared with those in vehicle-treated mice. However, baricitinib did not affect the differentiation of CD4+IL-4+ Th2 cells and CD4+CD25+Foxp3+ Treg cells. (E–H) Quantification of the mRNA expression of T-bet, GATA, RORγt, and Foxp3 in the baricitinib-treated groups and the control group. (I) MTS proliferation assays were performed to investigate the level of splenic lymphocyte proliferation. The results are displayed as the stimulation index. Baricitinib-treated groups exhibited significant reductions in proliferation. Quantitative data are the mean ± SEM. *p < 0.05; n = 6 per group. SEM, standard error of the mean.